STOCK TITAN

Sarepta Therapeutics, (SRPT) EPS by Year

SRPT NASDAQ

Sarepta Therapeutics,, Inc. lost $7.13 per diluted share in fiscal year 2025. This represents a decrease of 404.7% from the prior fiscal year. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a loss of $1.37 per diluted share. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Sarepta Therapeutics,, Inc. has filed alongside them.

FY2025 annual
EPS (Diluted) -$7.13
YoY -404.7%
5Y CAGR n/m
10Y CAGR n/m
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

SRPT EPS (Diluted) by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY1210-KFY1110-K
EPS (Diluted)-$1.37-$7.13-404.7%$2.34n/m-$5.80n/m-$8.03n/m-$5.15n/m-$7.11n/m-$9.71n/m-$5.46n/m-$0.86n/m-$5.49n/m-$5.20n/m-$3.39n/m-$3.31n/m-$5.14n/m-$0.12

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

SRPT EPS (Diluted) by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-KQ2'2410-KQ1'2410-KQ4'2310-K
EPS (Diluted)-$0.27n/m-$0.05-102.6%$2.88n/m-$3.93-362.0%-$0.50-247.1%$1.89+2600.0%-$4.60-1343.2%$1.50$0.34n/m$0.07n/m$0.37n/m$0.76n/m

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More Sarepta Therapeutics,, Inc. financials

Frequently Asked Questions

Sarepta Therapeutics,, Inc. lost $7.13 per diluted share in fiscal year 2025.

Sarepta Therapeutics,, Inc. (SRPT) diluted earnings per share fell by 404.7% year over year, from $2.34 to -$7.13 in fiscal year 2025.

Sarepta Therapeutics,, Inc. (SRPT) reported a loss of $1.37 per diluted share over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Across the 15 fiscal years this page covers, Sarepta Therapeutics,, Inc. (SRPT) diluted earnings per share went from -$0.12 in fiscal year 2011 to -$7.13 in fiscal year 2025.

Sarepta Therapeutics,, Inc. (SRPT) reported -$0.27 in diluted earnings per share in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Sarepta Therapeutics,, Inc. (SRPT) reported on that line in every period on record.